JPMorgan Chase set a GBX 5,500 ($78.75) price objective on AstraZeneca (LON:AZN) in a report published on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

AZN has been the subject of several other research reports. Jefferies Group upgraded shares of AstraZeneca from a hold rating to a buy rating and upped their price target for the stock from GBX 5,075 ($72.67) to GBX 5,600 ($80.18) in a research report on Monday, March 19th. UBS set a GBX 4,550 ($65.15) target price on shares of AstraZeneca and gave the company a neutral rating in a research report on Monday, January 8th. Liberum Capital reiterated a hold rating and issued a GBX 5,000 ($71.59) target price on shares of AstraZeneca in a research report on Friday, January 26th. Shore Capital reiterated a hold rating on shares of AstraZeneca in a research report on Monday, March 5th. Finally, Barclays reiterated an overweight rating and issued a GBX 6,300 ($90.21) target price on shares of AstraZeneca in a research report on Monday, December 18th. Four analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. AstraZeneca has a consensus rating of Hold and a consensus target price of GBX 5,226.87 ($74.84).

How to Become a New Pot Stock Millionaire

AstraZeneca stock opened at GBX 4,915.50 ($70.38) on Friday. AstraZeneca has a one year low of GBX 4,260 ($61.00) and a one year high of GBX 5,520 ($79.04).

The firm also recently disclosed a dividend, which was paid on Monday, March 19th. Stockholders of record on Thursday, February 15th were given a dividend of GBX 133.60 ($1.91) per share. This is a positive change from AstraZeneca’s previous dividend of $68.90. The ex-dividend date of this dividend was Thursday, February 15th. This represents a dividend yield of 2.8%.

In other AstraZeneca news, insider Philip A. J. Broadley acquired 415 shares of AstraZeneca stock in a transaction dated Friday, February 2nd. The stock was bought at an average price of GBX 4,846 ($69.39) per share, for a total transaction of £20,110.90 ($28,795.68).

TRADEMARK VIOLATION NOTICE: This report was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/04/16/jpmorgan-chase-analysts-give-astrazeneca-azn-a-gbx-5500-price-target.html.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.